CLPT

ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

ClearPoint Neuro, Inc. (CLPT) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -9.5
EV / EBITDA -10.6
Rev Growth YoY 36.3%
Gross Margin 61.4%
Price Return 3M -42.2%
Price Return 12M -44.5%
Catalyst Signal 0.00
Market Cap $281.1M
TTM Revenue $45.5M
Price / Sales 6.2
ROE -167.5%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) C+ (2.7) C+ (2.7) D+ (1.7) C+ (2.6) C+ (2.5)
2026-11-04 B- (3.0) C+ (2.7) C+ (2.8) C (2.3) C+ (2.7) C+ (2.7)
2026-10-28 B- (3.0) C (2.3) C+ (2.7) C+ (2.5) C+ (2.7) C+ (2.6)
2026-10-21 B- (3.0) C (2.3) C+ (2.7) C (2.2) C+ (2.6) C+ (2.6)
2026-10-14 B- (3.0) C (2.3) C+ (2.7) C (2.2) C+ (2.6) C+ (2.6)
Page 1 of 8
…